The following is an excerpt from a press release from Genentech. Read the press release in its entirety here.
Genentech has announced new data that will be presented at this year’s annual American Society of Hematology meeting held in San Diego from Dec. 1-4. Ten Genentech medicines will be featured in more than 70 abstracts, including 25 oral presentations, across 15 blood diseases.
“We look forward to sharing progress from our broad development program in hematology at ASH this year, reflecting our approach to understand mechanisms of blood diseases at the molecular level,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “We are excited to be presenting data across multiple blood diseases, including studies of several first-in-class medicines with the potential to transform standards of care and improve patients’ lives.”
Hemlibra® (emicizumab–kxwh), which represents the first new class of medicine in nearly 20 years for people with hemophilia A, will be featured in 12 abstracts at the congress. New data in children younger than 12 with hemophilia A with and without factor VIII inhibitors will be presented, including the full results from the pivotal HAVEN 2 study evaluating three different Hemlibra dosing options (once weekly, every two weeks or every four weeks) in children with hemophilia A with factor VIII inhibitors. Additionally, treatment preference data from the pivotal HAVEN 3 study in people with hemophilia A without factor VIII inhibitors and the pivotal HAVEN 4 study in people with hemophilia A with and without factor VIII inhibitors will be presented. Hemlibra was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia A without factor VIII inhibitors and is the only hemophilia treatment that can be administered subcutaneously and at multiple dosing options for all people with hemophilia A, with and without factor VIII inhibitors.
Read the press release in its entirety here.